Mary-Ellen Taplin, MD, presented “Treatment of Oligometastatic Disease” during the 27th Annual Southwest Prostate Cancer Symposium conference on October 17, 2024, in Scottsdale, Arizona.
/p>
How to cite: Taplin, Mary-Ellen. “Treatment of Oligometastatic Disease.” October 17, 2024. Accessed Apr 2026. https://grandroundsinurology.com/treatment-of-oligometastatic-disease-2/
Treatment of Oligometastatic Disease – Summary
Mary-Ellen Taplin, MD, presents a comprehensive discussion on the evolving treatment landscape for oligometastatic prostate cancer. In this 21-minute presentation, Dr. Taplin examines the role of systemic therapy, radiation to metastases, and primary tumor treatment, emphasizing recent advancements in PET imaging that redefine disease classification.
Dr. Taplin shares clinical trials that demonstrate that oligometastatic prostate cancer may be curable. Systemic therapy remains the standard of care, with androgen deprivation therapy plus androgen receptor pathway inhibitors significantly improving survival. She relays emerging evidence that supports metastasis-directed therapy using SBRT, delaying the need for androgen deprivation therapy. PET imaging revolutionizes staging, revealing previously undetectable disease and influencing treatment strategies.
Dr. Taplin believes more trials are needed to refine therapeutic approaches and ensure optimal patient outcomes in the PET imaging era.
About the 27th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Mary-Ellen Taplin, MD, is the Chair of the Executive Committee for Clinical Research in the Dana-Farber Cancer Institute (DFCI) and a Professor of Medicine at Harvard University in Boston, Massachusetts. In her role as Chair of the Executive Committee Clinical Research, Dr. Taplin oversees DFCI clinical research operations and mentors DFCI investigators in the development of trials that have the potential to improve outcomes for cancer patients. Her research in prostate cancer has focused on androgen receptor changes in the evolution of hormone-refractory prostate cancer and clinical trials of novel hormone therapy and chemotherapy with correlative molecular endpoints.
